Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

271P - Elderly patients and the watch and wait strategy in rectal cancer

Date

27 Jun 2024

Session

Poster Display session

Presenters

Dolores Maria Gomez Bradley

Citation

Annals of Oncology (2024) 35 (suppl_1): S106-S118. 10.1016/annonc/annonc1480

Authors

M. Sanchez del Cid1, L. Basbus1, L.M. Peña1, F. Cayol1, C. Vaccaro1, D.M. Gomez Bradley2

Author affiliations

  • 1 Hospital Italiano de Buenos Aires, Buenos Aires/AR
  • 2 Hospital Italiano de Buenos Aires - Centro de la Mujer, Buenos Aires/AR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 271P

Background

Rectal cancer (RC) is a common condition in the elderly population, representing a challenge as many of these patients are frail to undergo surgical treatments. There is increasing evidence of non-operative management of rectal tumors, but this age group is underrepresented in clinical trials. Objective: To evaluate clinical and surgical outcomes of treatments in patients over 70 years old with RC.

Methods

Retrospective, analytical study of patients with localized rectal cancer who underwent neoadjuvant therapy at the Italian Hospital of Buenos Aires between January 2007 and 2020.

Results

83 patients were analyzed, 54% (43) were women, median age 76 years IQR 72 - 81. 75% (59) were T3 or T4, 24% (19) N2. 80% underwent neoadjuvant therapy with radiotherapy and capecitabine, and 20% (16) underwent total neoadjuvant therapy (TNT). Treatment compliance was 95%. 11 patients experienced grade 3-4 toxicity. 54% (43) underwent surgery, 46% (36) patients pursued a watch and wait strategy with complete or near-complete clinical response, and 17 experienced local recurrence. Out of 60 operated patients, 15% (9) achieved complete pathological response. TNT strategy had an OR of 4.5 for achieving complete pathological response, 95% CI 1.04 - 19.85; p=0.048. Median follow-up was 44 months. 32 patients died. N2 was associated with lower survival (HR 2.34 95% CI 1.04-5 p=0.039). Complete clinical response was associated with higher survival (HR 0.3 95% CI 0.14-0.67 p=0.003).

Conclusions

A high treatment compliance rate was observed. Neoadjuvant therapy followed by watch and wait strategy was feasible in 46% of patients, avoiding surgery in 61% of them.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.